Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating

Catalyst Pharmaceuticals saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 92 the day before.

Investors Business Daily

Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating

Catalyst Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 83.

Investors Business Daily

Catalyst's New CEO Has Big Ideas For The Small Biotech

Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

How Top 7% Earnings Powerhouse Catalyst Pharmaceuticals Just Did It Again

Catalyst Pharmaceuticals doubled earnings expectations amid a strong launch for its new drug, Agamree. The biotech stock jumped Thursday.

Investors Business Daily

Catalyst Pharmaceuticals (CPRX) vs. Johnson & Johnson (JNJ): Predicting the Dominant Pharma Stock in 2024

Within the realm of burgeoning technological innovation and its seamless integration, the pharmaceutical industry emerges as a focal point for investors. Given this perspective, which of the two pharma stocks, Catalyst Pharmaceuticals (CPRX) and Johnson & Johnson (JNJ), holds greater potential for enduring returns in 2024? Read on….

StockNews.com

September Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals (CPRX) delivered a robust performance in its last reported quarter. So, is now the right entry point in the stock? Let’s look at its financial metrics to gauge its prospects.

StockNews.com

Catalyst Pharmaceuticals (CPRX): Is Now the Time to Buy This Pharma Stock?

Catalyst Pharmaceuticals (CPRX) reported robust second-quarter results, with its topline reaching an all-time high. Does that mean it's time to buy the pharma stock now? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Is Catalyst Pharmaceuticals (CPRX) a Buy in the Near Future?

Catalyst Pharmaceuticals (CPRX) witnessed significant bottom-line growth in the first quarter but missed expectations. Does the biopharmaceutical company deserve a place in your portfolio in the near future? Let’s look at its financial metrics to get an idea….

StockNews.com

AbbVie (ABBV) and Catalyst Pharmaceuticals (CPRX): Analyzing Investment Potential

The pharmaceutical industry’s inelastic demand for its products helps it to weather economic downturns. With fears of an impending recession playing on the minds of investors, it could be wise to buy fundamentally strong pharmaceutical stock AbbVie (ABBV). On the other hand, given its mixed fundamentals and profitability, it could…

StockNews.com

Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review

The Nasdaq hit a 2023 high as Google soared on AI announcements. But the market rally showed weakness too.

Investors Business Daily

Catalyst CEO Says 'We Hit The Ball Out Of The Park,' But Shares Of IBD 50 Stock Crash

No. 1 biotech stock Catalyst Pharmaceuticals put up a mixed first quarter Thursday, which took a heavy toll on the company's shares.

Investors Business Daily

ABNB, ANET, PANW Lead 11 Stocks Eyeing 53% To 667% Growth

With Q1 earnings reports ahead, ABNB stock joins ANET, PANW and eight other top growth stocks expecting 53% to 667% growth.

Investors Business Daily

No. 1 Biotech Catalyst Pharma Surges On 2023 Expectations

Leading biotech Catalyst Pharmaceuticals beat Wall Street's 2023 guidance expectations, and CPRX stock jumped Thursday.

Investors Business Daily

How Former IBD 50 Leader Catalyst Pharma Is Trying To Claw Back From A 29% Setback

Catalyst Pharmaceuticals added a second product to its lineup Wednesday with a $160 million deal. And CPRX stock advanced.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

IBD 50 Stocks To Watch: Biotech Leader Catalyst Pharmaceuticals Near New High

Biotech leader Catalyst Pharmaceuticals is one of the top stocks to watch, after rising past its latest buy point.

Investors Business Daily

Here Are 10 Biotech Stocks That Would Have Netted You $12,000 This Year

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best.

Investors Business Daily

Something Unusual Is Happening Right Now With Biotech Stocks

Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2022

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Catalyst Pharmaceuticals's Return On Capital Employed Insights

According to Benzinga Pro data Catalyst Pharmaceuticals (NASDAQ:CPRX) posted a 9.88% decrease in earnings from Q3. Sales, however, increased by 6.55% over the previous quarter to $38.31 million.

Benzinga

Recap: Catalyst Pharmaceuticals Q4 Earnings

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported its Q4 earnings results on Wednesday, March 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga

Earnings Preview For Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement. Analysts estimate that Catalyst Pharmaceuticals will report an earnings per share (EPS) of $0.12.

StockNews.com

Catalyst Pharmaceuticals: A Biotech Stock Worth Owning

Biopharmaceutical company Catalyst Pharmaceuticals (CPRX) has been advancing with the help of its product, FIRDAPSE. Furthermore, its top and bottom line grew in its last reported quarter. So, let’s discuss in detail why it could be wise to add CPRX to one’s portfolio now. Read on.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.